Abivax reveals promising results for Obefazimod in the treatment of ulcerative colitis

Abivax announced positive results from the Phase 3 ABTECT induction trials for its Obefazimod treatment, aimed at improving the quality of life of patients with active ulcerative colitis. Patients treated reported significant progress as early as week eight across various parameters, including bowel urgency, fatigue, and overall quality of life.

These trials demonstrated that 37% of patients taking 50 mg of obefazimod no longer experienced urgency, compared to only 18.1% in the placebo group. Furthermore, 47.6% reported an absence of nighttime bowel movements, marking a significant improvement compared to the placebo group.

Thanks to these encouraging results, Abivax plans to unveil detailed analyses at upcoming medical conferences, in order to continue the development of the treatment.